|
Novartis Wins Advisory Panel Support for Approval of Tobi Alternative
The FDA’s Anti-Infective Drugs Advisory Committee has recommended the FDA approve Novartis’ inhaler-based version of cystic fibrosis (CF) drug Tobi.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives